FDA lifts clinical hold on Arbutus Biopharma's AB-101
ABUS•The FDA lifted the clinical hold on Arbutus Biopharma's AB-101 investigational new drug application, allowing further U.S. clinical development. The company is evaluating next steps for the oral PD-L1 inhibitor, which completed a Phase 1a/1b trial.
